Anxiety Disorders
Pipeline by Development Stage
Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.
Key Trends
- Extreme market concentration: 68% of spending driven by one FXa inhibitor product
- Psychiatric and migraine therapies emerging as secondary growth drivers
- High clinical trial activity (8,279 trials) signals continued pipeline development
Career Verdict
Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | ELIQUIS (apixaban) | Bristol Myers Squibb | $18.3B | 68% | Launch | Stable | 15.0yr |
| 2 | INVEGA SUSTENNA (paliperidone palmitate) | Johnson & Johnson | $1.8B | 7% | Peak | Stable | 4.7yr |
| 3 | BRILINTA (ticagrelor) | AstraZeneca | $692M | 3% | Peak | Stable | 10.2yr |
| 4 | NUPLAZID (pimavanserin tartrate) | Acadia Pharmaceuticals | $596M | 2% | Peak | Stable | 10.9yr |
| 5 | INVEGA TRINZA (paliperidone palmitate) | Johnson & Johnson | $530M | 2% | Peak | Stable | 15.6yr |
Drug Class Breakdown
market-defining single product
stable mature class
niche but stable
specialty indication focus
emerging growth segment
stable with LOE risk
diverse small products
Career Outlook
StableNeurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.
Breaking In
Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.
For Experienced Professionals
Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.
In-Demand Skills
Best For
Hiring Landscape
Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.
Top Hiring Companies
By Department
Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.
Competitive Landscape
22 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 36 trials with date data
Clinical Trials (36)
Total enrollment: 9,547 patients across 36 trials
Trial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders.
Therapeutic Processes and Treatment Outcome in Adolescents With Anxiety Disorders
Fluoxetine vs CBT in Childhood Anxiety Disorders
Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
Study to Evaluate the Safety and Efficacy of GABITRIL Treatment in Adults With Generalized Anxiety Disorder.
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder
Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325
AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type)
A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-020)
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
Treating Stress and Anxiety in Individuals With Alcohol Use Disorder (AUD)
Concentration-QT Study of Paroxetine in Healthy Adults
Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects
Bioequivalence Trial of Alprazolam 0.5 mg Tablets
Bioequivalence Trial of Alprazolam 0.25 mg Tablets
Bioequivalence Study of Escitalopram Tablets 10 mg
Bioequivalence Trial of Alprazolam 2 mg Tablets
Reward Processes and Rehearsal in Exposure Therapy
Benzodiazepine Taper With Cognitive Behavioral Therapy in Patients Using Prescription Opioids
Respiratory Training in the Treatment of Transdiagnostic Pathological Anxiety
Parent Key Opinion Leaders to Increase Demand of Effective Treatments for Youth Anxiety
Threat Interpretation Bias as Cognitive Marker and Treatment Target in Pediatric Anxiety
Monitoring Telemedicine Platform in Patients With Anxiety Symptoms and Alcohol Use Disorder
Optimizing Exposure Therapy With Mental Rehearsal
Test of an Inhibitory Learning Model of Extinction in Treatment of Anxious Youth
TAO Outpatient Trial for Anxiety and Depression
Neurally Targeted Interventions to Reduce Early Childhood Anxiety
Delivery of Anxiety Disorder Treatment in Addictions Centers
WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture
Disseminating Evidence-based Practice to the Schools: CBT for Child Anxiety
Study Of Remission In Patients Treated For Generalized Anxiety Disorder
Related Jobs in Neurology
Executive Director/Vice President, Clinical Development
Corporate Strategy Intern
Promotional Materials Review Committee Manager
Director, Human Resources
Director/Senior Director, CMC, Drug Substance
Associate Director, Operational Procurement
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.